{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:32:19Z","timestamp":1757619139492,"version":"3.44.0"},"reference-count":21,"publisher":"BMJ","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2012,11,10]]},"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chronic hepatitis C infection (HCV) is common in injecting drug users and is a major cause of liver disease. Antiviral treatment can \u2018cure\u2019 HCV, but is frequently associated with side effects and requires regular monitoring. Non-attendance at hospital appointments is frequent. To try and improve attendance and increase the number of current and previous injecting drug users treated we developed three outreach clinics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To review the outcome of patients referred to the outreach clinics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Retrospective service review of three clinics at drug treatment centres in Newcastle and Northumberland. Data was collected on attendance rates, patient demographics, treatment rates and outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>141 referrals were received across the three sites with an overall attendance rate of 75% (106 patients, 79% men and median age 36), which compared favourably with that at our hospital (50%). All patients were on methadone\/subutex. 45% were infected with Genotype 1 HCV. 10% were cirrhotic. To date, 30% have started treatment and 21% are waiting to start or are still in workup. 13% elected to delay treatment due to early stage disease and 11% were not ready for treatment on psychological or social grounds. Only 12% failed to attend follow up after initial assessment. To date, 24 patients have completed full courses of treatment with sustained viral response in 13 patients. Results are awaited for seven patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The development of outreach clinics for HCV in drug treatment centres can substantially improve clinic attendance and increase access to treatment in this marginalised group.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/flgastro-2012-100282","type":"journal-article","created":{"date-parts":[[2012,12,14]],"date-time":"2012-12-14T22:41:29Z","timestamp":1355524889000},"page":"125-129","source":"Crossref","is-referenced-by-count":5,"title":["Improving access to treatment for patients with chronic hepatitis C through outreach"],"prefix":"10.1136","volume":"4","author":[{"given":"Ahmed Mohamed","family":"Elsharkawy","sequence":"first","affiliation":[{"name":"Liver Unit, University Hospitals Birmingham, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Miller","sequence":"additional","affiliation":[{"name":"Liver Unit, Freeman Hospital, Newcastle Upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hearn","sequence":"additional","affiliation":[{"name":"Plummer Court Addiction Service, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gertrud","family":"Buerstedde","sequence":"additional","affiliation":[{"name":"Bridge View Drug Treatment Centre, Newcastle upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Royal Victoria Infirmary, Newcastle Upon Tyne, UK"},{"name":"Institute of Cellular Medicine, Newcastle University, \u00a0Newcastle Upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"McPherson","sequence":"additional","affiliation":[{"name":"Liver Unit, Freeman Hospital, Newcastle Upon Tyne, UK"},{"name":"Institute of Cellular Medicine, Newcastle University, \u00a0Newcastle Upon Tyne, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2012,12,14]]},"reference":[{"key":"2025090708020908000_4.2.125.1","unstructured":"HPA. Hepatitis C in the UK. 2011."},{"key":"2025090708020908000_4.2.125.2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840360706"},{"key":"2025090708020908000_4.2.125.3","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.27831"},{"key":"2025090708020908000_4.2.125.4","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.1.131"},{"key":"2025090708020908000_4.2.125.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"2025090708020908000_4.2.125.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"2025090708020908000_4.2.125.7","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"2025090708020908000_4.2.125.8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6972"},{"key":"2025090708020908000_4.2.125.9","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C","volume":"8","author":"Sulkowski","year":"2011","journal-title":"Nat Rev Gastro Hep"},{"key":"2025090708020908000_4.2.125.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.04.021"},{"key":"2025090708020908000_4.2.125.11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.drugpo.2007.04.004","article-title":"Global estimates of prevalence of HCV infection among injecting drug users","volume":"18","author":"Aceijas","year":"2007","journal-title":"Int J Drug Pol"},{"key":"2025090708020908000_4.2.125.12","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jsat.2005.06.002","article-title":"The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone","volume":"29","author":"Sylvestre","year":"2005","journal-title":"J Sub Ab Treat"},{"key":"2025090708020908000_4.2.125.13","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.027383"},{"key":"2025090708020908000_4.2.125.14","unstructured":"DOH. High quality care for all: nHS next stage review. 2008."},{"key":"2025090708020908000_4.2.125.15","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/94.3.153"},{"key":"2025090708020908000_4.2.125.16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2893.2005.00698.x","article-title":"Clinical pathways for patients with newly diagnosed hepatitis C\u2014what actually happens","volume":"13","author":"Irving","year":"2006","journal-title":"J Viral Hep"},{"key":"2025090708020908000_4.2.125.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2004.00821.x"},{"key":"2025090708020908000_4.2.125.18","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.10.1500"},{"key":"2025090708020908000_4.2.125.19","first-page":"105","article-title":"Hepatitis services at an injecting drug user outreach clinic","volume":"114","author":"Moriarty","year":"2001","journal-title":"NZMJ"},{"key":"2025090708020908000_4.2.125.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009370"},{"key":"2025090708020908000_4.2.125.21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1365-2893.2009.01227.x","article-title":"The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre","volume":"17","author":"Tait","year":"2010","journal-title":"J Viral Hep"}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2012-100282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:02:19Z","timestamp":1757257339000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2012-100282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,14]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2,21]]},"published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1136\/flgastro-2012-100282"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2012-100282","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"type":"print","value":"2041-4137"},{"type":"electronic","value":"2041-4145"}],"subject":[],"published":{"date-parts":[[2012,12,14]]}}}